Penumbra Stock Jumps. It’s Being Bought by Boston Scientific for $14.5 Billion.

Yahoo Finance Published Updated Stocks
Sign in to save

Affected assets and topics

SHARES

Why it matters

Boston Scientific is acquiring Penumbra in a $14.5 billion deal, expanding its vascular medicine business through the addition of mechanical thrombectomy products.

Article tone

Neutral How the article is written, as reported by the source.

Expected market reaction

Bullish Confidence 90% How confidence is read Horizon: Short term Impact: Moderate

Market impact analysis based on bullish sentiment with 90% confidence.

Evidence trail

Evidence
Source Yahoo Finance
Claim Penumbra Stock Jumps. It’s Being Bought by Boston Scientific for $14.5 Billion.
AI inference Bullish · 90%
Generated 2026-01-15 16:16

AI provenance

Analysed by Llama 3.1 8B Instant (Groq) Methodology v1.0 Generated
Technical identifiers
Provider tag
groq-llama-3.1-8b-instant
Analysis version
groq-llama-3.1-8b-instant
Article id
33187

Original source

Boston Scientific has agreed to acquire Penumbra in a cash-and-stock deal worth $14.5 billion. The addition of Penumbra which makes mechanical thrombectomy products for vascular procedures, expands Boston Scientific’s vascular medicine business. The deal values Penumbra at $374 a share, with stockholders able to choose either $374 in cash or 3.8721 shares of Boston Scientific common stock.

Read the full article on Yahoo Finance

Original article published by Yahoo Finance on January 15, 2026. Analysis and insights provided by AnalystMarkets AI.

Related coverage